Target intelligence / Profile preview

Trans-activation response element of HIV-1 (TAR)

Target
TAR
Molecular classification
RNA regulatory element, Non-coding RNA, Other (RNA motif)
01

Overview

The Trans-activation response element of HIV-1 (TAR) is a highly conserved 59-nucleotide RNA stem-loop at the 5′ end of HIV-1 mRNAs. It is essential for efficient transcriptional elongation of viral genes by serving as a binding site for the viral Tat protein and host factors (such as cyclin T1 and CDK9), which recruit and stabilize RNA polymerase II on the viral promoter.[5][3][1] The TAR element’s interaction with Tat dramatically increases the levels of viral transcripts required for HIV-1 replication. Structural details, such as the UCU bulge and loop, are critical for Tat recognition and binding, and disruption of this interaction strongly inhibits viral replication.[5] TAR RNA can also produce viral microRNAs that modulate host cell processes, such as apoptosis, and may play a role in the viral life cycle and pathogenesis.[3][1] TAR is actively studied as a potential therapeutic target to block HIV-1 gene expression.

Other names
TARHIV-1 TARTransactivation response elementHIV-1 trans-activation response region
02

Mechanism of action

Inhibition of Tat–TAR binding, thereby blocking HIV-1 transcriptional activation; Modulation of RNA structure or stability to impair viral gene expression.

03

Biological functions

Regulation of viral transcriptionBinding site for Tat proteinEnhances HIV-1 gene expressionModulation of host cell gene expression (via microRNAs derived from TAR)
04

Disease associations

Infection (specifically HIV-1/AIDS)
05

Safety considerations

Targeting viral RNA structures can risk off-target effects on host RNAPotential emergence of viral resistance through mutation in the TAR region
06

Interacting drugs

Some investigational drugs (e.g., small molecules, peptides) target the Tat–TAR interaction, but specific clinically approved TAR-targeting drugs are not currently available. TAR is considered a potential drug target for novel antiviral compounds.
07

Biomarkers

TAR RNA itself can be indicative of active HIV-1 transcription in infected cells, but it is not widely used as a clinical biomarker.Monitoring Tat–TAR interaction, or TAR-derived microRNAs, has been explored experimentally.

Beyond the preview

Go deeper on Trans-activation response element of HIV-1 (TAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trans-activation response element of HIV-1 (TAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call